Benitec Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Benitec Biopharma Inc. (BNTC) on December 10, 2024, covering events occurring on December 9, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The primary material change reported is the effective amendment of the Company's Amended and Restated Certificate of Incorporation. Key details include:
- Authorization: The amendment authorizes the issuance of 5,000,000 shares of preferred stock with a par value of $0.0001.
- Approval: Stockholders approved this amendment at the 2024 Annual Meeting held on December 4, 2024.
- Effectiveness: The amendment was filed with the Delaware Secretary of State and became effective on December 9, 2024.
- Capital Structure: A corresponding change was made to the total number of authorized shares of capital stock.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or specific risk factors related to the amendment. The document references the definitive proxy statement on Schedule 14A filed on October 22, 2024, for a full summary of the material terms of the amendment.
Investor Verification Checklist
- Verify the specific rights and preferences of the newly authorized 5,000,000 preferred shares by reviewing the Schedule 14A proxy statement filed on October 22, 2024.
- Confirm the total authorized share count post-amendment to understand the dilution potential.
- Monitor future filings for any actual issuance of the newly authorized preferred stock.